Irvine, CA May 16, 2000 -- InVitro International (IVRO) announced today that revenues for each of its first two fiscal quarters in 2000 advanced to slightly more than $168,000. The nearly $337,000 first half sales total represents an increase of about 3% over same period 1999 figures. Operating profits for the December quarter were $7,787, and for the March quarter $13,967. These two quarters' results extend to six, the number of consecutive fiscal quarters that IVRO has posted operating income. Although net income in IVRO's second quarter was $8,949, the company posted a first half 2000 net loss of $95,249 due to an extraordinary, non-recurring write-off of $115,000 for a single doubtful receivable.
     In commenting on first half Y2K results, InVitro President, W. Richard Ulmer, said, "We were really quite pleased with overall financial progress in our core business. And we are particularly hopeful that the recent approvals and acceptances from several important U.S. Regulatory Agencies (EPA, FDA, Consumer Product Safety Commission & OSHA) will reinvigorate our now 15 year old non-animal testing business. Such approvals reflect exciting scientific support and validation that should help Corrositex more firmly establish itself as the only commercially available government approved alternative to animal testing for corrosion. We plan to extend such strong credibility to include our other core capability, the Irritection Assay System, for ocular and dermal irritation detection."
     This press release may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. These risks and uncertainties include, but are not limited to: acceptance of the Company's technology by customers or regulatory agencies, changes in market conditions and other competitive factors. Any such forward-looking statements are not guarantees of future performance.